BACKGROUND: The effects of bariatric surgery (BS) in metabolically healthy morbidly obese (MO) subjects are not well established. Against this background, we characterized the metabolic and inflammatory profiles of MO subjects with insulin sensitivity (IS) in the normal range, and evaluated the changes on these parameters following BS in this population. METHODS: We conducted a retrospective analysis of prospectively collected data in MO women undergoing BS between 2006 and 2010. Anthropometric, metabolic comorbidities, and inflammatory markers were compared at baseline and 12 months after BS, between 52 women (10.4%) presenting with a HOMA-IR < 2.94 (80th percentile reference population) (IS-MO group) and an age- and BMI-matched group of women (n = 52) with HOMA-IR > 2.94. RESULTS: The IS-MO women presented a more favorable metabolic and inflammatory profile as compared to the IR-MO group. However, an enlarged waist circumference (WC), a high-sensitivity C-reactive protein (hs-CRP) > 3 mg/dL, and metabolic syndrome (MS) were present in 100%, 90%, and 51.9% of the IS-MO group at baseline. At 12 months after surgery, all the MS components and hs-CRP improved in IS-MO subjects (p < 0.01). The prevalence of the MS in the IS-MO group significantly decreased (11%, p < 0.05) despite WC and hs-CRP being abnormal respectively in 53.3% and 20.0% of women in this group. CONCLUSIONS: In MO women, an IS in the normal range is associated with a limited protection from metabolic co-morbidities. Nonetheless, BS results in the amelioration of the altered metabolic and inflammatory profiles also in this group of subjects.
BACKGROUND: The effects of bariatric surgery (BS) in metabolically healthy morbidly obese (MO) subjects are not well established. Against this background, we characterized the metabolic and inflammatory profiles of MO subjects with insulin sensitivity (IS) in the normal range, and evaluated the changes on these parameters following BS in this population. METHODS: We conducted a retrospective analysis of prospectively collected data in MO women undergoing BS between 2006 and 2010. Anthropometric, metabolic comorbidities, and inflammatory markers were compared at baseline and 12 months after BS, between 52 women (10.4%) presenting with a HOMA-IR < 2.94 (80th percentile reference population) (IS-MO group) and an age- and BMI-matched group of women (n = 52) with HOMA-IR > 2.94. RESULTS: The IS-MO women presented a more favorable metabolic and inflammatory profile as compared to the IR-MO group. However, an enlarged waist circumference (WC), a high-sensitivity C-reactive protein (hs-CRP) > 3 mg/dL, and metabolic syndrome (MS) were present in 100%, 90%, and 51.9% of the IS-MO group at baseline. At 12 months after surgery, all the MS components and hs-CRP improved in IS-MO subjects (p < 0.01). The prevalence of the MS in the IS-MO group significantly decreased (11%, p < 0.05) despite WC and hs-CRP being abnormal respectively in 53.3% and 20.0% of women in this group. CONCLUSIONS: In MO women, an IS in the normal range is associated with a limited protection from metabolic co-morbidities. Nonetheless, BS results in the amelioration of the altered metabolic and inflammatory profiles also in this group of subjects.
Authors: J Vidal; A Ibarzabal; J Nicolau; M Vidov; S Delgado; G Martinez; J Balust; R Morinigo; A Lacy Journal: Obes Surg Date: 2007-08 Impact factor: 4.129
Authors: Courtney L Jennings; Estelle V Lambert; Malcolm Collins; Yael Joffe; Naomi S Levitt; Julia H Goedecke Journal: Obesity (Silver Spring) Date: 2008-04-17 Impact factor: 5.002
Authors: Nuria Barbarroja; Rosario López-Pedrera; Maria Dolores Mayas; Eduardo García-Fuentes; Lourdes Garrido-Sánchez; M Macías-González; Rajaa El Bekay; Antonio Vidal-Puig; Francisco J Tinahones Journal: Biochem J Date: 2010-08-15 Impact factor: 3.857
Authors: M Brochu; A Tchernof; I J Dionne; C K Sites; G H Eltabbakh; E A Sims; E T Poehlman Journal: J Clin Endocrinol Metab Date: 2001-03 Impact factor: 5.958
Authors: Ram Weiss; Sara E Taksali; Sylvie Dufour; Catherine W Yeckel; Xenophon Papademetris; Gary Cline; William V Tamborlane; James Dziura; Gerald I Shulman; Sonia Caprio Journal: J Clin Endocrinol Metab Date: 2005-03-29 Impact factor: 5.958
Authors: Gabriela Paredes-Turrubiarte; Antonio González-Chávez; Ruy Pérez-Tamayo; Beatriz Y Salazar-Vázquez; Vito S Hernández; Nayeli Garibay-Nieto; José Manuel Fragoso; Galileo Escobedo Journal: Clin Exp Med Date: 2015-04-18 Impact factor: 3.984
Authors: D Samocha-Bonet; V D Dixit; C R Kahn; R L Leibel; X Lin; M Nieuwdorp; K H Pietiläinen; R Rabasa-Lhoret; M Roden; P E Scherer; S Klein; E Ravussin Journal: Obes Rev Date: 2014-07-25 Impact factor: 9.213
Authors: Sophie H Narath; Selma I Mautner; Eva Svehlikova; Bernd Schultes; Thomas R Pieber; Frank M Sinner; Edgar Gander; Gunnar Libiseller; Michael G Schimek; Harald Sourij; Christoph Magnes Journal: PLoS One Date: 2016-09-01 Impact factor: 3.240